For years, individualized obstructive sleep apnea care has been more aspiration than routine practice. Pharmacologic therapies may help change that.
| # | Наименование новости | Тональность | Информативность | Дата публикации |
|---|---|---|---|---|
| 1 | Apnimed Appoints New CEO as Investigational OSA Therapy Nears FDA Decision | 0 | 5 | 22-06-2026 |
| 2 | Consumer Sleep Data Likely Houses Clues to Cases of Undiagnosed OSA | 0 | 6 | 30-06-2026 |
| 3 | Semaglutide Associated With Lower Incidence of OSA in Post Hoc Analysis | 2 | 6 | 26-06-2026 |
| 4 | Bryggs Medical Launches ULTepap 2 with Adjustable Pressure Settings | 0 | 5 | 06-07-2026 |
| 5 | SovaSage Releases AI-Powered Tool for CPAP Patient Management | 0 | 7 | 13-07-2026 |
| 6 | Health Canada Approves Zepbound for OSA in Adults With Obesity | 5 | 8 | 25-06-2026 |
| 7 | Drug Used Off-Label for Insomnia Improves Sleep But Impairs Next-Day Alertness in OSA Patients | 0 | 7 | 10-06-2026 |
| 8 | Narcolepsy Treatments Are Advancing. Can Access? | 0 | 7 | 14-07-2026 |
| 9 | Lilly’s Investigational Triple Agonist Retatrutide Reduces OSA Severity in Phase 3 Trial | 6 | 7 | 23-06-2026 |
| 10 | She Never Made It to Her Sleep Study | 0 | 7 | 24-06-2026 |